ACS Biomarker

ACS Biomarker ACS Biomarker B.V. is a Dutch biotechnology company focused on the discovery, validation and commercialization of novel biomarkers that improve prognosis and management of cardiac disease. The company conducts miRNA and protein-based biomarker research in its two research facilities in Amsterdam and Maastricht. Both laboratories are perfectly equipped for large scale, semi-automated screening of patient samples. ACS Biomarker established a close collaboration with two renowned cardiovascular research institutes, the Heart Failure Research Center of the AMC Amsterdam and CARIM of UMC Maastricht. The company out-licensed one of its first biomarker discoveries, Galectin-3 to BG Medicine Inc a NASDAQ listed company headquartered in Boston. The Galectin-3 in-vitro diagnostic immune-assay recently obtained FDA approval and is now available in the clinic.
 

Contact:
Heico Breek
CEO
ACS Biomarker
Meibergdreef 39
1105 AZ Amsterdam
Netherlands

 

Phone: +31 (0) 43 388 5811
Fax:     +31 (0) 43 388 5889
Phone Lab: +31 (0)433885813
E-mail: info@acsbiomarker.com

Contact:
Prof. Dr. Tilman M. Hackeng

CTO
ACS Biomarker
Meibergdreef 39
1105 AZ Amsterdam
Netherlands

 

Phone: +31 (0)43 388 5811
Fax:     +31 (0) 43 388 5889
Phone Lab: +31(0)433885813
E-mail: info@acsbiomarker.com